Edsivo FDA Approval Status
FDA Approved: No
Brand name: Edsivo
Generic name: celiprolol
Company: Acer Therapeutics Inc.
Treatment for: Vascular Ehlers-Danlos Syndrome
Edsivo (celiprolol) is a β-blocker (β1-andrenoceptor antagonist with partial β2 agonist activity) in development for the treatment of vascular Ehlers-Danlos syndrome (vEDS).
Development timeline for Edsivo
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.